Emergent BioSolutions (EBS) Research & Development (2011 - 2026)
Emergent BioSolutions (EBS) posted Research & Development of $9.4 million for Q3 2026, down 30.4% from $13.5 million a year earlier but up 2.2% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Research & Development (2011 - 2026) Analysis & Trends
For the trailing twelve months through Sep 30, 2026, Research & Development at Emergent BioSolutions was $41.2 million, down 17.9% year-over-year; for FY2025, it was $53.2 million, down 24.8% from FY2024.
- Annual Research & Development has declined for five consecutive years, with a five-year compound annual growth rate of -25.9% (FY2020 to FY2025).
- In prior years, Emergent BioSolutions' Research & Development was $70.7 million in FY2024 (-36.5%), $111.4 million in FY2023 (-40.8%), $188.3 million in FY2022 (-19.9%) and $235.2 million in FY2021 (-1.1%).
- Quarterly Research & Development has run from a low of $9.1 million in Q4 2024 to a high of $84.2 million in Q4 2021 over five years.
- On a year-over-year basis, Research & Development has declined in each of the last three quarters, with an average decline of 23.4% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was Q4 2021, with growth of 33.9%; the weakest was Q4 2024, with a decline of 69.0%.
- According to Business Quant data, Research & Development for the three prior quarters was $9.2 million (Q2 2026), $10.5 million (Q1 2026) and $12.1 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Emergent BioSolutions | 310.37 Mn | -370.73 Mn | 29.20 Mn | 9.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 9.40 Mn |
| Jun 30, 2026 | 9.20 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 12.10 Mn |
| Sep 30, 2025 | 13.50 Mn |
| Jun 30, 2025 | 12.50 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 9.10 Mn |
| Sep 30, 2024 | 13.80 Mn |
| Jun 30, 2024 | 32.70 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Dec 31, 2023 | 29.40 Mn |
| Sep 30, 2023 | 15.30 Mn |
| Jun 30, 2023 | 26.00 Mn |
| Mar 31, 2023 | 40.70 Mn |
| Dec 31, 2022 | 47.00 Mn |
| Sep 30, 2022 | 42.20 Mn |
| Jun 30, 2022 | 49.80 Mn |
| Mar 31, 2022 | 46.40 Mn |
| Dec 31, 2021 | 84.20 Mn |
API Access
Emergent BioSolutions Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();